These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30931172)

  • 21. Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer.
    Chung C
    Am J Health Syst Pharm; 2022 May; 79(10):717-718. PubMed ID: 35021198
    [No Abstract]   [Full Text] [Related]  

  • 22. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Patel KC; Hageman K; Cooper MR
    Am J Health Syst Pharm; 2014 Apr; 71(7):537-48. PubMed ID: 24644113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
    Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
    Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.
    Chudasama VL; Schaedeli Stark F; Harrold JM; Tibbitts J; Girish SR; Gupta M; Frey N; Mager DE
    Clin Pharmacol Ther; 2012 Oct; 92(4):520-7. PubMed ID: 22968044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of HER2 with [
    Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
    Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
    [No Abstract]   [Full Text] [Related]  

  • 28. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T; Teuwen LA; Rutten A; Dirix L
    Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 30. Trastuzumab deruxtecan beats trastuzumab emtansine in lowered disease progression, death.
    Cancer; 2022 Aug; 128(15):2852. PubMed ID: 35797061
    [No Abstract]   [Full Text] [Related]  

  • 31. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
    Doroshow DB; LoRusso PM
    Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NICE approves trastuzumab emtansine after deal with drug company.
    Kmietowicz Z
    BMJ; 2017 Jun; 357():j2930. PubMed ID: 28623237
    [No Abstract]   [Full Text] [Related]  

  • 35. Ado-trastuzumab emtansine approved for advanced breast cancer.
    Traynor K
    Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
    [No Abstract]   [Full Text] [Related]  

  • 36. Breast cancer brain metastases responding to primary systemic therapy with T-DM1.
    Bartsch R; Berghoff AS; Preusser M
    J Neurooncol; 2014 Jan; 116(1):205-6. PubMed ID: 24065570
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third-generation antibody drug conjugates for cancer therapy--a balancing act.
    Vankemmelbeke M; Durrant L
    Ther Deliv; 2016; 7(3):141-4. PubMed ID: 26893243
    [No Abstract]   [Full Text] [Related]  

  • 40. Trastuzumab emtansine for HER2-positive breast cancer.
    Venkatesan P
    Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.